Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models

Addiction Biology

Volumn 22, Issue 3, 2017, Pages 581-615

  Yardley, Megan M ^a   Ray, Lara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; novel therapeutics; valley of death

Indexed keywords

ACAMPROSATE; ALCOHOL; BACLOFEN; DISULFIRAM; DOXAZOSIN; DUTASTERIDE; GABAPENTIN; IBUDILAST; IVERMECTIN; LEVETIRACETAM; MECAMYLAMINE; MEMANTINE; MIFEPRISTONE; MINOCYCLINE; MIRTAZAPINE; NALMEFENE; NALTREXONE; OLANZAPINE; ONDANSETRON; OXYTOCIN; PIOGLITAZONE; PRAZOSIN; PREGABALIN; PSILOCYBINE; RIMONABANT; TOPIRAMATE; TRADIPITANT; UNINDEXED DRUG; VARENICLINE; ZONISAMIDE; DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG DEPENDENCE TREATMENT; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG TARGETING; EVENING DOSAGE; EXPERIMENTAL ANIMAL; HUMAN; LABORATORY TEST; MORNING DOSAGE; NONHUMAN; PREDICTIVE VALUE; ALCOHOL-RELATED DISORDERS; ANIMAL; DISEASE MODEL; PRECLINICAL STUDY; PROCEDURES;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; ANIMALS; CLINICAL STUDIES AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84958225941     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12349     Document Type: Article

References (295)

1. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims.(2009) DHHS US, FDA, CDER, CBER, CDRH (eds).
2. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37:504–508.
3. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi RGroup BS (2011) Dose–response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 46:312–317.
4. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915–1922.
5. Agrawal RG, Hewetson A, George CM, Syapin PJ, Bergeson SE (2011) Minocycline reduces ethanol drinking. Brain Beh Immun 25:S165–S169.
6. Ahmadi J, Ahmadi N (2002) A double blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. Ger J Psychiat 5:85–89.
7. Altshuler HL, Phillips PE, Feinhandler DA (1980) Alteration of ethanol self-administration by naltrexone. Life Sci 26:679–688.
8. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004a) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 173:32–40.
9. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiat 156:1758–1764.
10. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017.
11. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004b) A mult-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharm 24:421–428.
12. Arias A, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharm 30:318–322.
13. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104–106.
14. Asatryan L, Nam HW, Lee MR, Thakkar MM, Dar MS, Davies DL, Choi DS (2011) Implication of the purinergic system in alcohol use disorders. Alcohol Clin Exp Res 35:584–594.
15. Asatryan L, Yardley MM, Khoja S, Trudell JR, Huynh N, Louie SG, Petasis NA, Alkana RL, Davies DL (2014) Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol 17:907–916.
16. Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R (2005) The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacol 30:1104–1110.
17. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142–1149.
18. Bates B (2005) Physicians reluctant to prescribe for alcoholism. Internal Medicine News 42.
19. Beardsley PM, Lopez OT, Gullikson G, Flynn D (1994) Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol 11:389–395.
20. Becker HC, Ron D (2014) Animal models of excessive alcohol consumption: recent advances and future challenges. Alcohol 48:205–208.
21. Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Frankline KM, Becker HC (2013) Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol.
22. Besheer J, Lepoutre V, Hodge CW (2004) GABAB receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology (Berl) 174:358–366.
23. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573–579.
24. Bhutada P, Mundhada Y, Ghodki Y, Dixit P, Umathe S, Jain K (2012) Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of exposure to stress and modulation by mecamylamine. J Psychopharmacol 26:315–323.
25. Bhutada PS, Mundhada YR, Bansod KU, Dixit PV, Umathe SN, Mundhada DR (2010) Inhibitory influence of mecamylamine on the development and the expression of ethanol-induced locomotor sensitization in mice. Pharmacol Biochem Be 96:266–273.
26. Bilbao A, Robinson JE, Heilig M, Malanga CJ, Spanagel R, Sommer WH, Thorsell A (2015) A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. Biol Psychiat 77:850–858.
27. Bisaga A, Evans SM (2004) Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 172:16–24.
28. Bisaga A, Evans SM (2006) The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depen 83:25–32.
29. Blomqvist O, Ericson M, Engel JA, Soderpalm B (1997) Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur J Pharmacol 334:149–156.
30. Blomqvist O, Ericson M, Johnson DH, Engel JA, Soderpalm B (1996) Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol 314:257–267.
31. Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, Kranzler HR (2002) Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res 26:326–331.
32. Blomqvist O, Soderpalm B, Engel JA (1992) Ethanol-induced locomotor activity: involvement of central nicotinic acetylcholine receptors? Brain Res Bull 29:173–178.
33. Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19:600–606.
34. Bohn MJ, Kranzler HR, Beazoglou D, Staehler BA (1994) Naltrexone and brief counseling to reduce heavy drinking. Am J Addiction 3:91–99.
35. Bonnet U, Banger M, Leweke M, Specka M, Muller BW, Hashemi T, Nyhuis PW, Kutscher S, Burtscheidt W, Gastpar M (2003) Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharm 23:514–519.
36. Borsook D, Hargreaves R, Becerra L (2011) Can functional magnetic resonance imaging improve success rates in CNS drug discovery? Expert Opin Drug Discov 6:597–617.
37. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD (2011) Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 41:516–524.
38. Brasser SM, McCaul ME, Houtsmuller EJ (2004) Alcohol effects during acamprosate treatment: a dose–response study in humans. Alcohol Clin Exp Res 28:1074–1083.
39. Breslin FJ, Johnson BA, Lynch WJ (2010) Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology (Berl) 207:529–534.
40. Broadbent J, Harless WE (1999) Differential effects of GABAA and GABAB agonists on sensitization to the locomotor stimulant effects on ethanol in DBA/2 J mice. Psychopharmacology (Berl) 141:197–205.
41. Bujarski S, O'Malley SS, Lunny K, Ray LA (2013) The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psych 81:13–22.
42. Chester JA, Cunningham CL (1999) Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol Biochem Be 63:325–331.
43. Chi H, de Wit H (2003) Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res 27:780–786.
44. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000a) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcoholism 35:587–593.
45. Chick J, Howlett H, Morgan MY, Ritson B, Investigators U (2000b) United Kingdom multicentre acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcoholism 35:176–187.
46. Childs E, Roche DJ, King AC, de Wit H (2012) Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol Clin Exp Res 36:906–914.
47. Ciccocioppo R, Gehlert DR, Ryabinin A, Kaur S, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Economidou D, Stopponi S, Cannella N, Braconi S, Kallupi M, de Guglielmo G, Massi M, George DT, Gilman J, Hersh J, Tauscher JT, Hunt SP, Hommer D, Heilig M (2009) Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol 43:491–498.
48. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermúdez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR, Consortium ET (2005) Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci 21:2243–2251.
49. Coller JK, Hutchison MR (2012) Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Therapeut 134:219–245.
50. Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, Addolorato G, Gessa GL (2000) Ability of baclofen in reducing alcohol intake and withdrawal severity: I – preclinical evidence. Alcohol Clin Exp Res 24:58–66.
51. Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, Reali R, Gessa GL (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcoholism 33:126–130.
52. Colombo G, Serra S, Brunetti G, Vacca G, Carai MA, Gessa GL (2003) Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depen 70:105–108.
53. Colombo G, Vacca G, Serra S, Carai MAM, Gessa GL (2004) Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. Eur J Pharmacol 498:119–123.
54. Costall B, Jones BJ, Kelly ME, Naylor RJ, Onaivi ES, Tyers MB (1990) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Be 36:339–344.
55. Courtney KE, Schacht JP, Hutchinson K, Roche DJ, Ray LA (2015) Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol.
56. Covault J, Pond T, Feinn R, Arias AJ, Oncken C, Kranzler HR (2014) Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environment. Psychopharmacology (Berl) 231:3609–3618.
57. Crabbe JC, Harris RA, Koob GF (2011) Preclinical studies of alcohol binge drinking. Ann NY Acad Sci 1216:24–40.
58. Cunningham CL, Fidler TL, Hill KG (2000) Animal models of alcohol's motivational effects. Alcohol Res Health 24:85–92.
59. Davidson D, Palfai T, Bird C, Swift R (1999) Naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195–203.
60. De Sousa AA, De Sousa JA, Kapoor H (2008) An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 34:460–463.
61. DeMartini KS, Devine EG, DiClemente CC, Martin DJ, Ray LA, O'Malley SS (2014) Predictors of pretreatment commitment to abstinence: results from the COMBINE study. J Stud Alcohol Drugs 75:438–446.
62. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274–5278.
63. Dodd PR, Beckmann AM, Davidson MS, Wilce PA (2000) Glutamate-mediated transmission, alcohol, and alcoholism. Neurochem Int 37:509–533.
64. Dopico AM, Lovinger DM (2009) Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev 61:98–114.
65. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacol 28:755–764.
66. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362–1370.
67. Dyr W, Ligieza J, Kostowski W (2008) The effect of cannabinoid CB1 receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol 42:509–512.
68. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, Ciccocioppo R (2005) Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183:394–403.
69. Editorial (2010) Mechanism matters. Nat Med 16:347.
70. Edlund MJ, Booth BM, Han X (2012) Who seeks care where? Utilization of mental health and substance use disorder treatment in two national samples of individuals with alcohol use disorders. J Stud Alcohol Drugs 73:12.
71. Enoch MA, Johnson K, George DT, Schumann G, Moss HB, Kranzler HR, Goldman D (2009) Ethical considerations for administering alcohol or alcohol cues to treatment-seeking alcoholics in a research setting: can the benefits to society outweigh the risks to the individual? A commentary in the context of the National Advisory Council on Alcohol Abuse and Alcoholism – Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation (2005). Alcohol Clin Exp Res 33:1508–1512.
72. Ericson M, Blomqvist O, Engel JA, Soderpalm B (1998) Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol 358:189–196.
73. Evans SM, Bisaga A (2009) Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 33:19–30.
74. Evans SM, Levin FR, Brooks DJ, Garawi F (2007) A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 31:775–782.
75. Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ (2010) Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 34:2022–2034.
76. Fanelli D (2012) Negative results are disappearing from most disciplines and countries. Scientometrics 90:891–904.
77. Farook JM, Lewis B, Gaddis JG, Littleton JM, Barron S (2009) Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology 83:379–384.
78. Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S (2007) Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcoholism 42:296–300.
79. FDA (2006) Medical Review of Vivitrol. Government US (ed): Rockville, Maryland.
80. Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pattinati H, Strain EC, Devine E, Brunette MF, Kampman K, Tompkins A, Stout R, Group N-S (2012) A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 36:1421–1430.
81. Fish EW, Agoglia AE, Krouse MC, Muller RG, Robinson JE, Malanga CJ (2014) Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice. Behav Pharmacol 25:61–70.
82. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, Crosby K, Morreale M, Trivette A (2004) Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 28:1517–1523.
83. Ford MM, Beckley EH, Nickel JD, Eddy S, Finn DA (2008) Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis. Drug Alcohol Depen 97:73–85.
84. Ford MM, Fretwell AM, Nickel JD, Mark GP, Strong MN, Yoneyama N, Finn DA (2009) The influence of mecamylamine on ethanol and sucrose self-administration. Neuropharmacology 57:250–258.
85. Fowler JS, Volkow ND, Kassed CA, Chang L (2007) Imaging the addicted human brain. Sci Pract Perspect 3:4–16.
86. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R (2012) Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36:351–360.
87. Freeland CS, Sharpe AL, Samson HH, Porrino LJ (2001) Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 25:277–282.
88. Froehlich JC, Harts J, Lumeng L, Li TK (1990) Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Be 35:385–390.
89. Froehlich JC, Hausauer BJ, Federoff DL, Fischer SM, Rasmussen DD (2013) Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake. Alcohol Clin Exp Res 37:1552–1560.
90. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 215:655–663.
91. Fuller RK, Hiller-Sturmhofel S (1999) Alcoholism treatment in the United States. An overview. Alcohol Res Health 23:69–77.
92. Furberg BD, Furberg CD (2007) Evaluating Clinical Research: All That Glitters Is Not Gold, 2 edn. Springer Science and Business Media.
93. Gabriel KI, Cunningham CL (2005) Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res 29:75–80.
94. Garbutt JC, Kampov-Polevoi AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34:1849–1857.
95. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293:1617–1625.
96. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharm 22:592–598.
97. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129–137.
98. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Helig M (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536–1539.
99. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D, Helig M, Ramchandani VA, Geyer C, Spero DE, Singley E, O'Malley SS, Bishai R, Rawlings RR, Kunos G (2010) Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) 208:37–44.
100. Gessa GL, Muntoni G, Collu M, Vargiu L, Mereu G (1985) Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 348:201–203.
101. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G (2004) Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcoholism 40:46–53.
102. Gianoulakis C, de Waele J, Thavundayil J (1996) Implication of the endogenous opioid system in excessive ethanol consumption. Alcohol 13:19–23.
103. Gilpin NW, Koob GF (2008) Neurobiology of alcohol dependence. Alcohol Res Health 31:185–195.
104. Gonzales RA, Job MO, Doyon WM (2004) The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Therapeut 103:121–146.
105. Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18:10663–10671.
106. Grady C (2005) Payment of clinical research subjects. J Clin Invest 115:1681–1687.
107. Grant BF, Dawson DA, Stinson FS, Chou P, Dufour MC, Pickering RP (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depen 74:223–234.
108. Gual A, He Y, Torup L, van den Brink W, Mann K, Group ES (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23:1432–1442.
109. Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcoholism 36:413–418.
110. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381–1387.
111. Gupta T, Syed YM, Revis AA, Miller SA, Martinez M, Cohn KA, Demeyer MR, Patel KY, Brzezinkska WJ, Rhodes JS (2008) Acute effects of acamprosate and MPEP on ethanol drinking-in-the-dark in male C57BL⁄6J mice. Alcohol Clin Exp Res 32:1992–1998.
112. Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS (2009) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 205:53–62.
113. Harris RA, Mihic SJ, Dildy-Mayfield JE, Machu TK (1995) Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. FASEB J 9:1454–1462.
114. Harwood H (2000) Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. In: NIAAA Newsletter: Available at: http://www.niaaa.nih.gov.
115. Hasin DS, Stinson FS, Ogburn E, Grant BF (2007) Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiat 64:830–842.
116. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Therapeut 111:855–876.
117. Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30:399–406.
118. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharm 21:287–292.
119. Hendrickson LM, Zhao-Shea R, Tapper AR (2009) Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl) 204:563–572.
120. Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129:99–111.
121. Heyser CJ, Moc K, Koob GF (2003) Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 28:1463–1471.
122. Heyser CJ, Schulteis G, Durbin P, Koob GF (1998) Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18:125–133.
123. Holter SM, Danysz W, Spanagel R (1996) Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314:R1–R2.
124. Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD (1991) Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage. Alcohol 8:355–367.
125. Hungund BL, Yaragudri KV (2009) Role of the Endocannabinoid System in Alcohol-Related Behaviors. The Open Neuropharmcology Journal 2:31–39.
126. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31:1310–1317.
127. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A (2001) Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 155:27–34.
128. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882–1888.
129. Ingman K, Korpi ER (2006) Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine. Eur J Pharmacol 534:133–140.
130. Jacquot C, Croft AP, Prendergast MA, Mulholland P, Shaw SG, Little HJ (2008) Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption. Alcohol Clin Exp Res 32:2107–2116.
131. Janak PH, Wolf FW, Heberlein U, Pandey SC, Logrip ML, Ron D (2006) BIG news in alcohol addiction: new findings on Growth factor pathways BDNF, insulin, and GDNF. Alcohol Clin Exp Res 30:214–221.
132. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y (2014) Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav R 38:1–16.
133. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA (2009) Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A 106:11318–11323.
134. Ji D, Gilpin NW, Richardson HN, Rivier C, Koob GF (2008) Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 19:1–12.
135. Johnson B (2010) Medication treatment of different types of alcoholism. Am J Psychiat 167:630–639.
136. Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34–56.
137. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677–1685.
138. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963–971.
139. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift R (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651.
140. Kamdar NK, Miller SA, Syed YM, Bhayana R, Gupta T, Rhodes JS (2007) Acute effects of Naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. Psychopharmacology (Berl) 192:207–217.
141. Kamens HM, Anderson J, Picciotto MR (2010) The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL⁄6J mice. Alcohol Clin Exp Res 34:2053–2060.
142. Kamens HM, Phillips TJ (2008) A role for neuronal nicotinic acetylcholine receptors in ethanol-induced stimulation, but not cocaine-or methamphetamine-induced stimulation. Psychopharmacology (Berl) 196:377–387.
143. Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L (2015) Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol.
144. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiat 60:92–99.
145. Kiianmaa K, Hoffman PL, Tabakoff B (1983) Antagonism of the behavioral effects of ethanol by naltrexone in BALB/c, C57BL/6, and DBA/2 mice. Psychopharmacology (Berl) 79:291–294.
146. Killeen TK, Brady KT, Gold PB, Simpson KT, Faldowski RA, Tyson C, Anton RF (2004) Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 28:1710–1717.
147. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 129:15–22.
148. Kirschbaum C, Pirke KM, Hellhammer DH (1993) The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28:76–81.
149. Knapp CM, Mercado M, Markley T, Crosby S, Ciraulo DA, Kornetsky C (2007a) Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Be 87:65–72.
150. Knapp DJ, Overstreet DH, Breese GR (2007b) Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res 31:582–595.
151. Koenig HN, Olive MF (2004) The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions. Psychoneuroendocrino 29:999–1003.
152. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238.
153. Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22:1074–1079.
154. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C (2003) Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27:1150–1155.
155. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS (2007) Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiat 62:694–697.
156. Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, Tsoy M, Bespalov A, Slavina TY, Grineko AA, Petrakis IL, Pittman B, Gueorguieva R, Zvartau EE, Krystal JH (2007) Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiat 164:519–523.
157. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734–1739.
158. Kuzmin A, Jerlhag E, Liljequist S, Engel J (2009) Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl) 203:99–108.
159. Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H (2008) A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone, and acamprosate in the treatment of alcohol dependence. Alcohol Alcoholism 43:53–61.
160. Lallemand F, Soubrie PH, De Witte PH (2001) Effects of CB1cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res 25:1317–1323.
161. Larsson A, Svensson L, Soderpalm B, Engel JA (2002) Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol 28:157–167.
162. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Australia 176:530–534.
163. Le AD, Corrigall WA, Watchus J, Harding S, Juzytsch W, Li TK (2000) Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res 24:155–163.
164. Le AD, Funk D, Harding S, Juzytsch W, Fletcher PJ, Shaham Y (2006) Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 186:82–92.
165. Le AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, Shaham Y (2011) Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology (Berl) 218:89–99.
166. Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21:435–444.
167. Leggio L, Ferrulli A, Cardone S, Nesci A, Miceli A, Malandrino N, Capristo E, Canestrelli B, Monteleone P, Kenna GA, Swift RM, Addolorato G (2012) Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol 17:452–464.
168. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA (2014) Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiat 76:734–741.
169. Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, Addolorato G, Swift RM, Kenna GA (2013) A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Bichem Be 103:784–791.
170. Lehrer D, Leschke J, Lhachimi S, Vasiliu A, Weiffen B (2007) Negative results in social science. Eur Polit Sci 6:51–68.
171. Leon AC, Davis LL, Kraemer HC (2011) The role and interpretation of pilot studies in clinical research. J Psychiat Res 45:626–629.
172. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F, Hillemand B (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcoholism 25:613–622.
173. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A (2012) Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17:513–527.
174. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R, NCIG (2013) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7:277–286.
175. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179–1188.
176. Lukoyanov NV, Paula-Barbosa MM (2001) Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci Lett 309:45–48.
177. Maccioni P, Bienkowski P, Carai MA, Gessa GL, Colombo G (2008) Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depen 95:284–287.
178. Maccioni P, Fantini N, Carai MAM, Gessa GL, Colombo G (2009) Suppressing effect of the cannabinoid CB1 receptor antagonist, rimonabant, on alcohol self-administration in alcohol-preferring rats. The Open Neuropharmcology Journal 2:40–44.
179. MacKillop J (2006) Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res 30:1315–1321.
180. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiat 73:706–713.
181. Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, Guerriero L, Bruschi A, De Filippis R, Pozzi G, Di Giannantonio M, Bria P, Janiri L (2010) Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 105:288–299.
182. Martinotti G, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P (2008) Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 25:608–618.
183. Mason BJ, Goodman AM, Chabac S, Lehert P (2006) Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiat Res 40:383–393.
184. Mason BJ, Light JM, Williams LD, Drobes DJ (2009) Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14:73–83.
185. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: A randomized clinical trial JAMA 174:70–77.
186. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162–1167.
187. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiat 56:719–724.
188. Matosin N, Frank E, Engel M, Lum JS, Newell KA (2014) Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Dis Model Mech 7:171–173.
189. Mayfield J, Ferguson L, Harris RA (2013) Neuroimmune signaling: a key component of alcohol abuse. Curr Opin Neurobiol 23:513–520.
190. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ (2000) Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22:480–492.
191. McGregor IS, Bowen MT (2012) Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav 61:331–339.
192. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiat 66:185–190.
193. Middaugh LD, Kelley BM, Cuison ER, Groseclose CH (1999) Naltrexone effects on ethanol reward and discrimination in C57BL/6 mice. Alcohol Clin Exp Res 23:456–464.
194. Miller PM, Book SW, Stewart SH (2011) Medical treatment of alcohol dependence: a systematic review. Int J Psychiat Med 42:227–266.
195. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489–497.
196. Mitchell JM, Grossman LE, Coker AR, Messing RO (2012a) The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharm 32:269–272.
197. Mitchell JM, O'Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL (2012b) Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med 4:116ra116.
198. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012c) Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 223:299–306.
199. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addiction 10:258–268.
200. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987) Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96:122–126.
201. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone's effects on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:1386–1394.
202. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634–1647.
203. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101:1451–1462.
204. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96:1565–1573.
205. Moykkynen T, Korpi ER (2012) Acute effects of ethanol on glutamate receptors. Basic Clin Pharmacol Toxicol 111:4–13.
206. Myrick H, Anton R, Voronin K, Wang W, Henderson S (2007) A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 31:221–227.
207. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of naltrexone and ondansetron on alcohol cue–induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiat 63:466–475.
208. Nadal R, Chappell AM, Samson HH (1998) Effects of nicotine and mecamylamine microinjections into the nucleus accumbens on ethanol and sucrose self-administration. Alcohol Clin Exp Res 22:1190–1198.
209. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E, Investigators KACT (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcoholism 38:135–141.
210. Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM (2011) κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology 61:35–42.
211. Ngyuen SA, Malcom R, Middaugh LD (2007) Topiramate reduces alcohol consumption by C57BL/6 mice. Synapse 61:150–156.
212. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR (2007) Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharm 27:507–512.
213. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo–pituitary–adrenocortical axis. Psychopharmacology (Berl) 160:19–29.
214. O'Neil ML, Beckwith LE, Kincaid CL, Rasmussen DD (2013) The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats. Alcohol Clin Exp Res 37:202–212.
215. Oka M, Hirouchi M, Tamura M, Sugahara S, Oyama T (2013) Acamprosate {monocalcium bis(3-acetamidopropane-1-sulfonate)} reduces ethanol-drinking behavior in rats and glutamate-induced toxicity in ethanol-exposed primary rat cortical neuronal cultures. Eur J Pharmacol 718:323–331.
216. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW (2002) Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 437:55–61.
217. World Health Organization (2011) Global status report on alcohol and health Gogek J, Hopkins D (eds): Switzerland. pp 1–286.
218. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462.
219. Paille F, Martini H (2014) Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehab 5:87–94.
220. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcoholism 30:239–247.
221. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203–214.
222. Pava MJ, Woodward JJ (2012) A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 46:185–204.
223. Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov-Polevoi A, Casey RL, Fender T, Garbutt JC (2013) Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 37:484–489.
224. Pelc I, Verbanck P, Le Bon O, Garvrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiat 171:73–77.
225. Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P (1998) Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol 354:135–143.
226. Pierce RC, Kumaresan V (2006) The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav R 30:215–238.
227. Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM (2013) Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depen 133:754–758.
228. Plebani JG, Oslin DW, Lynch KG (2011) Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study. Am J Addiction 20:330–336.
229. Plebani JG, Ray LA, Morean ME, Corbin WR, MacKillop J, Amlung M, King AC (2012) Human laboratory paradigms in alcohol research. Alcohol Clin Exp Res 36:972–983.
230. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537–1546.
231. Pratt WM, Davidson D (2005) Does participation in an alcohol administration study increase risk for excessive drinking? Alcohol 37:135–141.
232. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC (2009) The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 33:264–272.
233. Ray LA, Bujarski S, Chin PF, Miotto K (2012) Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37:445–455.
234. Ray LA, Hutchison KE, Tartter M (2010) Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des 16:2149–2158.
235. Resnik DB, McCann DJ (2015) Deception by research participants. N Engl J Med 373:1192–1193.
236. Richter C, Hinzpeter A, Schmidt F, Kienast T, Preuss UW, Plenge T, Heinz A, Schaefer M (2010) Levetiracetam for the treatment of alcohol withdrawal syndrome. J Clin Psychopharm 30:720–725.
237. Roberto M, Gilpin NW, O'Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF (2008) Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci 28:5762–5771.
238. Robinson G, Most D, Ferguson LB, Mayfield J, Harris RA, Blednov YA (2014) Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. Int Rev Neurobiol 118:13–39.
239. Robinson JE, Chen M, Stamatakis AM, Krouse MC, Howard EC, Faccidomo S, Hodge CW, Fish EW, Malanga CJ (2013) Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL/6J mice. Neuropsychopharmacology 38:1322–1333.
240. Rothman KJ, Michels KB (1994) The continuing unethical use of placebo controls. N Engl J Med 331:394–398.
241. Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM, Jimenez-Arriero MA, Alamo C (2010) Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 33:250–253.
242. Russo SJ, Mazei-Robison MS, Albes JL, Nestler EJ (2009) Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 56:73–82.
243. Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P (2013) mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res 247:9–16.
244. Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, Afshar M, Richambault C, Sickels L, Devine E, Ciraulo DA (2009) The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Use 35:316–319.
245. Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickels L, Uwodukunda E, Richambault C, Koplow J, Ciraulo D (2008) The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Ab 34:441–447.
246. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18:879–885.
247. Serra S, Brunetti G, Pani M, Vacca G, Carai MA, Gessa GL, Colombo G (2002) Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol 443:95–97.
248. Sharrett-Field L, Butler TR, Berry JN, Reynolds AR, Prendergast MA (2013) Mifepristone pretreatment reduces ethanol withdrawal severity in vivo. Alcohol Clin Exp Res 37:1417–1422.
249. Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE (2012) Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacol 37:906–918.
250. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33:255–263.
251. Sinha R, Catapano D, S.S OM (1999) Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology (Berl) 142:343–351.
252. Skelly MJ, Weiner JL (2014) Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use. Brain Beh 4:468–483.
253. Soderpalm B, Ericson M (2013) Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci 13:127–161.
254. Sommer C, Seipt C, Spreer M, Blumke T, Markovic A, Junger E, Plawecki MH, Zimmerman US (2015) Laboratory alcohol self-administration experiments do not increase subsequent real-life drinking in young adult social drinkers. Alcohol Clin Exp Res 39:1057–1063.
255. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF, Investigators AS (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharm 28:317–324.
256. Spanagel R (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89:649–705.
257. Spanagel R, Holter SM, Allingham K, Landgraf R (1996a) Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305:39–44.
258. Spanagel R, Putzke J, Stefferi A, Schobitz B, Zieglgansberger W (1996b) Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 305:45–50.
259. Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F (2014) Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 39:783–791.
260. Spanagel R, Zieglgansberger W, Hundt W (1996c) Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 305:51–56.
261. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104:12518–12523.
262. Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M, Ruggeri B, Helig M, Demopulos G, Gaitanaris G, Massi M, Ciccocioppo R (2011) Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiat 69:642–649.
263. Stopponi S, Somaini L, Cippitelli A, de Guglielmo G, Kallupi M, Cannella N, Gerra G, Massi M, Ciccocioppo R (2012) Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl) 220:87–96.
264. Suchankova P, Steensland P, Fredriksson I, Engel JA, Jerlhag E (2013) Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. PLoS One 8:e71284.
265. Sullivan GM, Feinn R (2012) Using effect size- or why the p value is not enough. J Grad Med Educ 4:279–282.
266. Szabo G, Kovacs GL, Telegdy G (1987) Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal. Alcohol Alcoholism 22:71–74.
267. Tabakoff B, Hoffman PL (2000) Animal models in alcohol research. Alcohol Res Health 24:77–84.
268. Tanchuck MA, Yoneyama N, Ford MM, Fretwell AM, Finn DA (2011) Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. Alcohol 45:33–44.
269. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcoholism 35:202–209.
270. Thiele TE, Badia-Elder NE (2003) A role for neuropeptide Y in alcohol intake control: evidence from human and animal research. Physiol Behav 79:95–101.
271. Thorsell A (2007) Neuropeptdie Y (NPY) in alcohol intake and dependence. Peptides 28:480–483.
272. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32:58–66.
273. Todd S, Whitehead A, Stallard N, Whitehead J (2001) Interim analyses and sequential designs in phase III studies. Brit J Clin Pharmaco 51:394–399.
274. Tomkins DM, Le AD, Sellers EM (1995) Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology (Berl) 117:479–485.
275. Tsai G, Coyle JT (1998) The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 49:173–184.
276. Umhau JC, Schwandt ML, Usala J, Geyer C, Singley E, George DT, Helig M (2011) Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropharmacology 36:1178–1186.
277. Unsalan N, Saglam E, Kayir H, Uzbay TI (2008) Effects of olanzapine on ethanol withdrawal syndrome in rats. Eur J Pharmacol 579:208–214.
278. Vadnie CA, Park JH, Gawad NA, Ho AMC, Hinton DJ, Choi DS (2014) Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders. Front Neurosci 8:1–25.
279. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7.
280. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr, Logrip ML, Rivier C, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Helig M, Koob GF (2012) Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32:7563–7571.
281. Verplaetse TL, Rasmussen DD, Froehlich JC, Czachowski CL (2012) Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. Alcohol Clin Exp Res 36:881–886.
282. Walker BM, Koob GF (2007) The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res 31:11–18.
283. Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643–652.
284. Weiss F, Porrino LJ (2002) Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 22:3332–3337.
285. Weiss RD, S.S OM, Hosking JD, LoCastro JS, Swift R, COMBINE Study Research Group. (2008) Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 69:878–884.
286. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347.
287. Witkiewitz K, Saville K, Hamreusm K (2012) Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag 8:45–53.
288. Wouda JA, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D, Schoffelmeer ANM, Pattij T, De Vries TJ (2011) Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) 216:267–277.
289. Wyatt LR, Finn DA, Yardley MM, Khoja S, Asatryan L, Alkana RL, Davies DL (2014) Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice. Neurochem Res 39:1127–1139.
290. Yardley M, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis NA, Bortolato M, Davies DL (2012) Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology 63:190–201.
291. Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies DL (2014) Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. NeuroReport 25:1018–1023.
292. Ye J, Ponnudurai R, Schaefer R (2001) Ondansetron: a selective 5-HT3 receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 7:199–213.
293. Yoneyama N, Crabbe JC, Ford MM, Murillo A, Finn DA (2008) Voluntary ethanol consumption in 22 inbred mouse strains. Alcohol 42:149–160.
294. Young EM, Mahler S, Chi H, de Wit H (2005) Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin Exp Res 29:58–65.
295. Zalewska-Kaszubska J, Bajer B, Czarnecka E, Dyr W, Gorska D (2011) Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: A preliminary study. Physiol Behav 102:538–541.